DEPOSIT AGREEMENT by and among DBV TECHNOLOGIES S.A. AND CITIBANK, N.A., as Depositary, AND THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [DATE], 2014Deposit Agreement • October 15th, 2014 • DBV Technologies S.A. • Biological products, (no disgnostic substances) • New York
DEPOSIT AGREEMENT, dated as of [DATE], 2014, by and among (i) DBV TECHNOLOGIES S.A., a company organized and existing under the laws of the Republic of France, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America acting in its capacity as depositary, and any successor depositary hereunder (the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 23rd, 2018 • DBV Technologies S.A. • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”) is made as of March 23, 2018, by and between DBV Technologies S.A., a French Société Anonyme (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
SALES AGREEMENTSales Agreement • May 2nd, 2022 • DBV Technologies S.A. • Biological products, (no disgnostic substances) • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 13th, 2022 • DBV Technologies S.A. • Biological products, (no disgnostic substances) • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of June 8, 2022 by and among DBV Technologies S.A., a société anonyme organized under the laws of the French Republic (the “Company”), and the “Investors” named in the Securities Purchase Agreement, dated as of the date hereof, by and among the Company and the Investors identified on Schedule I attached thereto (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
Re: Termination of the Development Collaboration and License AgreementDBV Technologies S.A. • March 7th, 2024 • Biological products, (no disgnostic substances)
NESTEC and DBV entered into the Agreement to establish a collaboration whereby DBV would develop a diagnostic test for CMPA using DBV’s proprietary Viaskin™ Technology, and NESTEC would receive a license to commercialize such diagnostic product. Through no fault of either party, and after both parties having used Commercially Reasonable Efforts to pursue the development and commercialization of a diagnostic test for CMPA, the parties desire to cease all activities under the Agreement, including, without limitation, all Development activities, and the parties desire to terminate the Agreement in its entirety in accordance with the terms of this letter (this “Letter”), effective as of the last date of signature hereof, (the “Effective Date”).
DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT By and Between DBV TECHNOLOGIES and NESTEC S.A.Development Collaboration and License Agreement • March 22nd, 2017 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
This DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT (together with the exhibits hereto, this “Agreement”) is entered into on this 27th day of May, 2016 (the “Effective Date”), by and between NESTEC S.A., with a place of business at Avenue Nestlé 55, 1800 Vevey, Switzerland (“NESTEC”) and DBV TECHNOLOGIES, S.A., with a place of business at 177-181 avenue Pierre Brossolette 92120 Montrouge France (“DBV”). NESTEC and DBV may each be referred to herein individually as a “Party” and collectively as the “Parties.”
COMMERCIAL LEASECommercial Lease • March 7th, 2024 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
SCI DANTON MALAKOFF, a French non-trading real estate company with share capital of 1,000 euros, registered in the Paris Trade and Companies Register under number 838 690 071, whose registered office is located at 30 avenue Kleber 75116 PARIS,
OFFICE LEASEOffice Lease • April 29th, 2015 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
GENERALI VIE, a limited company with a capital 299,197, 104.00 Euros, with its head office situated at PARIS (75009) – 11, Boulevard Haussmann, and registered in the Commercial and Companies Register under number 602 062 481,
DBV TECHNOLOGIES SA ORDINARY SHARES (€0.10 NOMINAL VALUE) MASTER UNDERWRITING AGREEMENT AMONG DBV TECHNOLOGIES SA, U.S. UNDERWRITERS AND INTERNATIONAL UNDERWRITERS October , 2014Master Underwriting Agreement • October 15th, 2014 • DBV Technologies S.A. • Biological products, (no disgnostic substances) • New York
This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers, directors, employees, agents and controlling persons thereof, and no other person will have any right or obligation under this Agreement.
DBV TECHNOLOGIES S.A. STOCK OPTION AGREEMENT AND PLANStock Option Agreement and Plan • March 16th, 2018 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
Pursuant to the Stock Option grant notice (the “Grant Notice”) and this Stock Option agreement (this “Agreement and Plan”), DBV Technologies (the “Company”) has granted Optionee an option (the “Stock Option”) under this Agreement and Plan referenced in the Grant Notice to purchase/subscribe the number of shares of the Company’s Ordinary Shares, €0.10 nominal value per share (each, a “Share”) indicated in the Grant Notice at the exercise price indicated in the Grant Notice. The Stock Option is granted to the Optionee effective as of the date of grant set forth in the Grant Notice (the “Grant Date”).. Capitalized terms in this Agreement shall have the meaning specified in the Grant Notice unless a different meaning is specified herein.
DBV TECHNOLOGIES S.A. 3,552,500 Ordinary Shares and 3,329,784 American Depositary Shares, each representing one half of one Ordinary Share UNDERWRITING AGREEMENTUnderwriting Agreement • April 4th, 2019 • DBV Technologies S.A. • Biological products, (no disgnostic substances) • New York
DBV Technologies S.A., a société anonyme incorporated under the laws of France, registered with the registre du commerce et des sociétés of Nanterre under number 441 772 522, the registered office of which is 177-181, avenue Pierre Brossolette, 92120 Montrouge, France (the “Company”), proposes to issue and sell, in a capital increase reserved to specified categories of investors with a view to distribution in accordance with the terms hereof to the several underwriters named in Schedule II-1 (the “U.S. Underwriters”) and Schedule II-2 (the “European Underwriters”) hereto (together, the “Underwriters”), for whom you are acting as managers (the “Managers”), (i) 3,552,500 ordinary shares, €0.10 nominal value per share (the “Ordinary Shares”) of the Company (the “European Firm Shares”), and (ii) 1,664,892 Ordinary Shares (the “U.S. Firm Shares”), which Ordinary Shares may be in the form of American Depositary Shares (“ADSs”). In addition, at the option of the Underwriters, the Company has
SHAREHOLDERS’ AGREEMENT BETWEEN FONDS STRATEGIQUE D’INVESTISSEMENT Pierre-Henri BENHAMOU Bertrand DUPONT PHYS Participations and DBCS Participations IN THE PRESENCE OF DBV TECHNOLOGIES March 9, 2012Shareholders’ Agreement • September 22nd, 2014 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
Fonds Stratégique d’Investissement, a limited company registered in the Trade and Companies Register of Paris under number 509 584 074, having its head office at 56, rue de Lille, 75007 Paris, represented by Thomas Devedjian and Maïlys Ferrère, duly authorized for the purposes hereof,
DBV TECHNOLOGIES S.A. ORDINARY SHARES (€0.10 NOMINAL VALUE) MASTER UNDERWRITING AGREEMENT BY AND AMONG DBV TECHNOLOGIES S.A. AND UNDERWRITERSMaster Underwriting Agreement • July 14th, 2015 • DBV Technologies S.A. • Biological products, (no disgnostic substances) • New York
This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers, directors, employees, agents and controlling persons thereof, and no other person will have any right or obligation under this Agreement.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 13th, 2022 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
EXECUTIVE AGREEMENTExecutive Agreement • March 17th, 2021 • DBV Technologies S.A. • Biological products, (no disgnostic substances) • New Jersey
This EXECUTIVE AGREEMENT (the “Agreement”) between DBV Technologies, Inc. (the “Company”), and Pharis Mohideen (the “Executive”) is effective on July 22, 2019 (the “Effective Date”).
FIRST AMENDMENT TO THE EXECUTIVE AGREEMENT OF DANIEL TASSEExecutive Agreement • March 17th, 2021 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO THE EXECUTIVE AGREEMENT OF DANIEL TASSE the “Amendment”) is entered into this 27th day of June 2019 (the “Effective Date”), by and between DANIEL TASSE (the “Executive”) and DBV TECHNOLOGIES S.A. (the “Company”).
BETWEEN THE UNDERSIGNED:DBV Technologies S.A. • March 7th, 2024 • Biological products, (no disgnostic substances)
DBV Technologies, a French public limited company (société anonyme) with share capital of 9,625,355.30 euros, registered in the Nanterre Trade Register under number 441 772 522, with its head office at 171-181, avenue Pierre Brossolette 92120 Montrouge, represented by Caroline Danière, in her capacity as Group Human Resources Director, duly authorized to act on behalf of DBV Technologies.
LEASE AGREEMENTLease Agreement • March 7th, 2024 • DBV Technologies S.A. • Biological products, (no disgnostic substances) • New Jersey
This LEASE AGREEMENT (this “Lease”) is dated MARCH 28, 2022, and is between SIG 106 LLC, a New Jersey limited liability company (“Landlord”), and DBV TECHNOLOGIES, INC., a Delaware corporation (“Tenant”).
EXECUTIVE AGREEMENTExecutive Agreement • March 17th, 2021 • DBV Technologies S.A. • Biological products, (no disgnostic substances) • New Jersey
This EXECUTIVE AGREEMENT (the “Agreement”) between DBV Technologies S.A. (the “Company”), and Daniel Tasse (the “Executive”) is effective as of November 29, 2018 (the “Effective Date”).
ASSIGNMENT, DEVELOPMENT AND CO-OWNERSHIP AGREEMENT VAL/08/06-09/01Ownership Agreement • August 29th, 2014 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
DBV TECHNOLOGIES, a limited company with a share capital of €250,493.00, registered with the Corporate and Trade Register of Paris under number 441 772 522 R.C.S. NANTERRE, with its head office located at 104 Avenue Victor Hugo 92100 Boulogne Billancourt, acting through its legal representative,
COMMERCIAL LEASECommercial Lease • September 22nd, 2014 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
SELECTINVEST 1, a real estate investment trust with variable capital, with registered office in PARIS (75008) – 173, boulevard Haussmann, registered under number 784 852 261 R.C.S. [Registry of Trade and Companies] of PARIS.
AMENDMENT TO THE DEVELOPMENT COLLABORATION AND LICENSE AGREEMENTAnd License Agreement • April 1st, 2019 • DBV Technologies S.A. • Biological products, (no disgnostic substances)
This AMENDMENT (the “Amendment”) entered into on 12 July 2018 (the “Effective Date”) is an amendment to the DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT dated 27th day of May, 2016, by and between NESTEC S.A., with a place of business at Avenue Nestlé 55, 1800 Vevey, Switzerland (“NESTEC”) and DBV TECHNOLOGIES, S.A., with a place of business at 177-181 avenue Pierre Brossolette 92120 Montrouge France (“DBV”) (the “Agreement”). NESTEC and DBV may each be referred to herein individually as a “Party” and collectively as the “Parties.”
